Lannett Prepares For Insulin Glargine Trial
Pivotal Clinical Trial For Biosimilar Lantus Rival Expected To Begin In March 2022
Lannett says it is ready to kick off the pivotal clinical trial for the biosimilar insulin glargine candidate it is developing with HEC, after the US FDA completed the safety review of the product’s investigational new drug application.
